คลังข้อมูลการวิจัยการเกษตรไทย

ผู้แต่ง Cheewanan Lertpiriyasuwat

เผยแพร่โดย

1 Department of Disease Control, Institute of Research, Knowledge Management and Standards for Disease Control, Ministry of Public Health, Thailand 2 Department of Disease Control, Bureau of AIDS, TB and STIs, Ministry of Public Health, Thailand 3 Department of Medical Sciences, National Institute of Health, Ministry of Public Health, Thailand

เผยแพร่เมื่อ ไม่ระบุวันที่เผยแพร่

หน่วยงาน ไม่ระบุหน่วยงาน

งานวิจัยที่แนะนำ Optimization of genotyping by phenotypic analysis of clinical HIV-1 subtype CRF01_AE isolates from South-East Asia Circulation of HIV-1 Multiple Complexity Recombinant Forms Among Female Sex Workers Recently Infected with HIV-1 in Thailand Use of dried blood spot specimens for in-house HIV drug resistance genotyping assay among infants in Thailand Thai Cosmetopoeia การขับเคลื่อนเศรษฐกิจสังคมไทยด้วยการสร้างสรรคุณค่าเครื่องสำอางตามเอกลักษณ์ท้องถิ่น External Quality Assessment Scheme for HIV-1 Drug Resistance Genotyping in Thailand Thai Open GLAM Prevalence of HIV infection, access to HIV care, and response to antiretroviral therapy among partners of HIV-infected individuals in Thailand Practices in security and confidentiality of HIV/ AIDS patients’ information: A national survey among staff at HIV outpatient clinics in Vietnam Prevalence of primary HIV drug resistance in Thailand detected by short reverse transcriptase genotypic resistance assay Stigmatizing attitudes toward people living with HIV among general adult Thai population: Results from the 5 th Thai National Health Examination Survey (NHES)

คัดลอก URL

ชื่อเรื่อง (EN):	National Survey of Pretreatment HIV-Drug Resistance in Thai HIV-1-Infected Adults
ผู้แต่ง / หัวหน้าโครงการ (EN):	Cheewanan Lertpiriyasuwat
บทคัดย่อ (EN):	Background: WHO recommended a method to estimate nationally representative pretreatment HIV drug resistance (PDR) prevalence for providing evidence in selection of first-line antiretroviral treatment regimens. This study aimed to assess PDR prevalence in Thai HIV-1 infected adults. Methods: We conducted a cross-sectional survey among patients aged 18 years and above who were antiretroviral drug (ARV)-naïve or prior-exposed to ARVs and interrupted for more than three months. Twenty hospitals were sampled using probability proportional to size of patients initiating antiretroviral therapy. Then a consecutive enrolment of eligible patients was done during August 2016-February 2017. Plasma specimens were collected for genotyping. Results: Of 327 patients with genotypic results, most of them were men (48.6%), naive (84.4%) and infected with HIV-1 subtype CRF01_AE (90.7%). Median CD4 count was 160cells/mm3 and median viral load was 83,696 copies/ml. Overall PDR prevalence was 8.2% (95% CI 4.5-14.7). The prevalence was 0.2% (95% CI 0.1-0.3) for any nucleoside reverse-transcriptase inhibitors (NRTIs), 8.1% (95% CI 4.3-14.5) for any non-NRTIs (NNRTIs), 1.2% (95% CI 0.2-7.1) for any protease inhibitors (PIs), 0.1% (95% CI 0.0-0.2) for both NRTIs and NNRTIs, and 1.1% (95% CI 0.2-7.5) for both PIs and NNRTIs. The most common surveillance drug resistance mutations were Y181C (2.3%), followed by K103N (2.0%) and G190A (1.1%), respectively. Conclusion: NNRTIs resistance prevalence was less than 10% which was a WHO recommendation’s cut-off point for changing the first-line regimen. However, PDR surveillance should be conducted every three year and PDR prevention interventions should be implemented.
บทคัดย่อ:	ไม่พบข้อมูลจากหน่วยงานต้นทาง
ภาษา (EN):	en
เอกสารแนบ (EN):	http://nih.dmsc.moph.go.th/research/showimgdetil.php?id=517
เผยแพร่โดย (EN):	1 Department of Disease Control, Institute of Research, Knowledge Management and Standards for Disease Control, Ministry of Public Health, Thailand 2 Department of Disease Control, Bureau of AIDS, TB and STIs, Ministry of Public Health, Thailand 3 Department of Medical Sciences, National Institute of Health, Ministry of Public Health, Thailand
คำสำคัญ (EN):	Survey; Pretreatment HIV drug resistance; HIV-1; Thai
เจ้าของลิขสิทธิ์ (EN):	National Institute of Health, Department of Medical Science